EAU 2021: Is Nuclear Medicine Taking over the Treatment of Metastatic Prostate Cancer? PRLT Could Do Much More If Applied Earlier and Repetitive

(UroToday.com) The European Association of Urology (EAU) 2021 Virtual Annual Meeting included a joint session of the EAU and the Canadian Urological Association and a presentation by Dr. Christian La Fougere discussing prostate radioligand therapy and its use earlier in the disease process. Dr. La Fougere notes that the theranostic key-lock principle includes a target (ie. membrane-antigens, PSMA), a ligand (ie. small molecules, PSMA-617), a linker, and a chelator (ie. PET-reporting unit, ⁶⁸Ga, ⁶⁴Cu, ¹⁸F; or therapeutic unit, ⁹⁰Y, ¹⁷⁷Lu, ²¹³Bi, ²²⁵Ac):